Medically reviewed by Drugs.com. Last updated on Sep 8, 2020.
(res LIZ ue mab)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous [preservative free]:
Cinqair: 100 mg/10 mL (10 mL)
Brand Names: U.S.
- Interleukin-5 Antagonist
- Monoclonal Antibody, Anti-Asthmatic
Reslizumab is an interleukin-5 antagonist (IgG4 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils (a cell type associated with inflammation and an important component in the pathogenesis of asthma). Reslizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of reslizumab action in asthma has not been definitively established.
Vd: ~5 L
Undergoes proteolytic degradation via enzymes into small peptides and amino acids.
Use: Labeled Indications
Asthma: Add-on maintenance treatment of severe asthma in adults with an eosinophilic phenotype
Limitations of use: Not indicated for treatment of other eosinophilic conditions or for the relief of acute bronchospasm or status asthmaticus.
Hypersensitivity to reslizumab or any component of the formulation
Asthma: IV: 3 mg/kg once every 4 weeks.
Refer to adult dosing.
Remove vial from refrigerator; to minimize foaming, do not shake. Solution is clear to slightly hazy/opalescent, colorless to slight yellow liquid; proteinaceous particles may be present in the solution that appear translucent to white; do not administer if discolored. Withdraw calculated volume from vial and, to minimize foaming, add slowly to 50 mL NS infusion bag. Gently invert the bag; do not shake. Compatible bags are polyvinylchloride (PVC) or polyolefin. The time between preparation and administration should not exceed 16 hours. Do not mix with other drugs. Vials are single-use only; discard unused portion.
IV: For IV infusion only. Allow diluted solution to reach room temperature. Use an infusion set with an in-line, low protein-binding filter (pore size: 0.2 micron); compatible filters are polyethersulfone (PES), polyvinylidene fluoride (PVDF), nylon, and cellulose acetate. Infuse over 20 to 50 minute period (may vary depending on total volume being infused) and then flush the IV administration set with NS after the infusion is finished. Do not administer as an IV push or bolus and do not infuse concomitantly in the same IV line with other agents. Observe patient during and for an appropriate time following infusion.
Formulation may contain sucrose.
Store intact vials in refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Protect from light; store in original package. After dilution in NS in infusion bag, administer immediately or store in a refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature up to 25°C (77°F), protected from light, for up to 16 hours.
There are no known significant interactions.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Immunologic: Antibody development (5%)
Neuromuscular & skeletal: Increased creatine phosphokinase (20%; transient), myalgia (1%)
Respiratory: Oropharyngeal pain (3%)
<1%, postmarketing, and/or case reports: Anaphylaxis
ALERT: U.S. Boxed WarningAnaphylaxis:
Anaphylaxis has been observed with reslizumab infusion in 0.3% of patients in placebo-controlled clinical studies. Anaphylaxis was reported as early as the second dose of reslizumab. Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after reslizumab administration by a health care professional prepared to manage anaphylaxis. Discontinue reslizumab immediately if the patient experiences signs or symptoms of anaphylaxis.
Concerns related to adverse effects:
• Anaphylaxis [US Boxed Warning]: Anaphylaxis was reported in 0.3% of asthma patients in placebo-controlled studies; these events were observed during or within 20 minutes after completion of infusion, and may occur as early as the second dose. Observe patients for an appropriate period of time after administration. Manifestations included dyspnea, decreased oxygen saturation, wheezing, vomiting, skin and mucosal involvement, including urticaria. If severe systemic reactions, including anaphylaxis occur, discontinue administration immediately and provide appropriate medical treatment.
• Malignancies: Malignancies were observed during clinical trials with the majority being diagnosed within less than 6 months of drug exposure; neoplasms observed were diverse with no predominant histologic type.
• Asthma: Not indicated for the treatment of acute asthma symptoms (eg, acute bronchospasm) or acute exacerbations, including status asthmaticus.
• Helminth infections: It is unknown if administration of reslizumab will influence a patient's immune response against parasitic infections. Therefore, patients with preexisting helminth infections should undergo treatment of the infection prior to initiation of reslizumab therapy. Patients who become infected during reslizumab treatment and do not respond to anti-helminth therapy should discontinue reslizumab until the infection resolves.
Concurrent drug therapy issues:
• Corticosteroids: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of reslizumab. Reductions in corticosteroid dose should be gradual, if appropriate. Clinicians should note that a reduction in corticosteroid dose may be associated with withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Anaphylaxis/hypersensitivity reactions (during and after infusion); peak flow, and/or other pulmonary function tests; monitor for signs of infection
Reslizumab is a humanized monoclonal antibody (IgG4). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).
Uncontrolled asthma is associated with adverse events in pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low-birth-weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes) (ERS/TSANZ [Middleton 2020]; GINA 2020).
Use of monoclonal antibodies for the treatment of asthma in pregnancy may be considered when conventional therapies are insufficient; use of an agent other than reslizumab may be preferred (ERS/TSANZ [Middleton 2020]). The long half-life of reslizumab should be considered if required for a pregnant woman.
Data collection to monitor pregnancy and infant outcomes associated with asthma and the medications used to treat asthma in pregnancy is ongoing. Health care providers are encouraged to enroll exposed pregnant females in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (877-311-8972 or https://mothertobaby.org). Patients may also enroll themselves.
What is this drug used for?
• It is used to treat asthma.
• Do not use this drug to treat an asthma attack. Use a rescue inhaler. Talk with your doctor.
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
• Throat pain
• Infusion reaction
• Shortness of breath
• Passing out
• Pale skin
• Fast heartbeat
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine’s uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.
More about reslizumab
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- En Español
- 8 Reviews
- Drug class: interleukin inhibitors
Other brands: Cinqair